Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EVITA: Vedolizumab for ICI Colitis
NCT06841705Phase 2Recruiting
- Start
- Jul 2025
- Primary completion
- Jul 2026
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of vedolizumab in immune checkpoint inhibitor-induced colitis. Started Jul 2025; status: recruiting.
02
Drugs
vedolizumab
03
Conditions
immune checkpoint inhibitor-induced colitis
Beyond the preview
Go deeper on NCT06841705.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06841705.